Human Plasma-Derived Mannose-Binding Lectin: A Phase I Safety and Pharmacokinetic Study

H. Valdimarsson, T. Vikingsdottir, P. Bang, S. Saevarsdottir, J. E. Gudjonsson, O. Oskarsson, M. Christiansen, L. Blou, I. Laursen, C. Koch

Rannsóknarafurð: Framlag til fræðitímaritsGreinritrýni

90 Tilvitnanir (Scopus)


Mannose-binding lectin (MBL) is an important component of innate immunity that can bind to certain sugar residues on the surface of many types of pathogenic micro-organisms. On binding, MBL generates opsonic activity mainly through activation of the complement system. Genetically determined MBL deficiency is very common and can be associated with increased susceptibility to a variety of infections, especially in children and immunosuppressed individuals. The potential benefits of MBL reconstitution therapy therefore need to be evaluated. We have carried out a phase I safety and pharmacokinetic study on 20 MBL-deficient healthy adult volunteers. The MBL was prepared from plasma of nonremunerated, voluntary Danish donors tested and found negative for hepatitis B surface antigen, antibodies to human immunodeficiency virus (HIV) and hepatitis C virus. Each volunteer received a total of 18 mg of MBL in three 6 mg doses given intravenously, once weekly over a period of 3 weeks. The volunteers were closely monitored at the University Hospital in Reykjavik for 8 h after each infusion and daily thereafter for 5 days after each infusion. No adverse clinical or laboratory changes were observed in any of the 20 participants, and frequent measurements did not reveal any signs of infusion-associated complement activation. No antibodies to MBL, HIV or hepatitis viruses were observed 24 weeks after the last infusion. Serum MBL levels increased up to normal levels (1200-4500 ng/ml) immediately after each infusion, but the half-life of the infused MBL was highly variable, ranging from 18 to 115 h (mean 69.6). It is concluded that infusion of purified MBL as prepared by Statens Serum Institut (SSI) is safe. However, adults have to be given at least 6 mg twice or thrice weekly for maintaining protective MBL levels assumed to be about 1000 ng/ml.

Upprunalegt tungumálEnska
Síður (frá-til)97-102
FræðitímaritScandinavian Journal of Immunology
Númer tölublaðs1
ÚtgáfustaðaÚtgefið - jan. 2004


Sökktu þér í rannsóknarefni „Human Plasma-Derived Mannose-Binding Lectin: A Phase I Safety and Pharmacokinetic Study“. Saman myndar þetta einstakt fingrafar.

Vitna í þetta